Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma

Keith Ian Quintyne; Shirley Baker; Fintan Wallis; Rajnish Gupta

doi:10.1136/bcr.11.2011.5202

Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma

BMJ Case Rep. 2012 Jun 28:2012:bcr1120115202. doi: 10.1136/bcr.11.2011.5202.

Authors

Keith Ian Quintyne¹, Shirley Baker, Fintan Wallis, Rajnish Gupta

Affiliation

¹ Medical Oncology Department, Mid-Western Regional Hospital, and Stokes Research Institute, University of Limerick, Limerick, Ireland. keithi.quintyne@hse.ie

Abstract

The authors herein report the case of a 32-year-old man with advancing metastatic malignant melanoma, who has progressed through all previous lines of therapy, presenting with ongoing respiratory tract symptoms of exertional shortness of breath and cough. CT restaging confirmed clinical findings of deteriorating pulmonary disease; histological review revealed V600E BRAF mutation. He was started on targeted biological therapy with BRAF inhibitor GSK2118436, and is having a good clinical and radiological response without significant lasting toxicity.

Publication types

Case Reports

MeSH terms

Adult
Dose Fractionation, Radiation
Humans
Imidazoles / therapeutic use*
Lung Neoplasms / genetics
Lung Neoplasms / secondary
Lung Neoplasms / therapy*
Male
Melanoma / genetics
Melanoma / secondary
Melanoma / therapy*
Oximes / therapeutic use*
Pneumonectomy
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics
Skin Neoplasms / genetics
Skin Neoplasms / pathology
Skin Neoplasms / surgery*

Substances

Imidazoles
Oximes
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
dabrafenib